UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050102
Receipt number R000057080
Scientific Title Comparison of the Usefulness of EUS-FNA/B for Histological Diagnosis Using Sonotip Topgain and Acquire.
Date of disclosure of the study information 2023/01/23
Last modified on 2023/01/23 03:42:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of the Usefulness of EUS-FNA/B for Histological Diagnosis Using Sonotip Topgain and Acquire.

Acronym

Comparison of the Usefulness of EUS-FNA/B for Histological Diagnosis Using Sonotip Topgain and Acquire.

Scientific Title

Comparison of the Usefulness of EUS-FNA/B for Histological Diagnosis Using Sonotip Topgain and Acquire.

Scientific Title:Acronym

Comparison of the Usefulness of EUS-FNA/B for Histological Diagnosis Using Sonotip Topgain and Acquire.

Region

Japan


Condition

Condition

The patients requiring EUS-FNA/B

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Endoscopic ultrasound-assisted fine needle aspiration (EUS-FNA) is a standardized diagnostic method for pancreatic diseases. Recently, the Franseen needle puncture needle (Acquire; Boston Scientific) has been introduced to improve the specimen collection. On the other hand, the crowned tip of the Franseen needle makes it difficult to insert the needle into a lesion, and puncture techniques are required. A new puncture needle (Sonotip Topgain; Medicos Hirata Inc.) with the same Franseen needle shape but with a sharpened tip was introduced to the market, which reduced the difficulty of puncturing while maintaining the specimen collection rate. The following is a summary of the results of the study.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Degree of organization frustration

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

EUS-FNA/B performed once each on Sonotip Topgain and Acquire

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

95 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Age18 to 95
2. Those planning EUS-FNA for pancreatic tumors, biliary tumors, lymph nodes, gastric submucosal tumors, etc.
3. Those who, after receiving a full explanation of their participation in this study, have obtained written consent

Key exclusion criteria

1. Plt 50000 mm3 PT(INR) 1.5
2. High risk bleeding for EUS FNA
3. Pregnant patient
4. Doctors doesn't approve.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Hironao
Middle name
Last name Ookubo

Organization

Juntendo Nerima hospital

Division name

Gastroenterology

Zip code

177-8521

Address

3-1-10 Takanodai Nerima-ku Tokyo, Japan

TEL

03-5923-3111

Email

ytakasa@juntendo.ac.jp


Public contact

Name of contact person

1st name Yusuke
Middle name
Last name Takasaki

Organization

Juntendo Nerima hospital

Division name

Gastroenterology

Zip code

177-8521

Address

3-1-10 Takanodai Nerima-ku Tokyo, Japan

TEL

03-5923-3111

Homepage URL


Email

ytakasa@juntendo.ac.jp


Sponsor or person

Institute

Juntedo Nerima Hospital

Institute

Department

Personal name



Funding Source

Organization

Boston Scientific, Medicos Hirata

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Good clinical practice center

Address

3-1-3 Hongo Bunkyo-ku Tokyo, Japan

Tel

03-3813-3111

Email

igakubu.rinri1@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 10 Month 28 Day

Date of IRB

2022 Year 12 Month 09 Day

Anticipated trial start date

2022 Year 12 Month 09 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 01 Month 23 Day

Last modified on

2023 Year 01 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057080


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name